Chinese Expert Consensus on Immunotherapy for Hepatocellular Carcinoma (2021 Edition)

BACKGROUND: Hepatocellular carcinoma (HCC) is one of the most common malignancies in China. Most HCC patients are first diagnosed at an advanced stage, and systemic treatments are the mainstay of treatment. SUMMARY: In recent years, immune checkpoint inhibitors have made a breakthrough in the system...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Yu, Sun, Juxian, Wu, Mengchao, Lau, Wan Yee, Zheng, Shusen, Wang, Xue-Hao, Chen, Xiaoping, Fan, Jia, Dong, Jiahong, Cai, Jianqiang, Chen, Minshan, Chen, Yongjun, Cheng, Zhangjun, Dai, Chaoliu, Shan, Jianzhen, Du, Cheng-You, Fang, Chihua, Hu, Heping, Ji, Zhili, Jia, Weidong, Li, Gong, Li, Jing, Li, Jiangtao, Liu, Chang, Liu, Fubao, Ma, Yong, Mao, Yilei, Niu, Zuoxing, Shen, Jie, Shi, Jie, Shi, Xuetao, Song, Wenjie, Sun, Hui-Chuan, Tan, Guang, Tao, Ran, Wang, Xiaohu, Wen, Tianfu, Wu, Liqun, Xia, Jinglin, Xiang, Bang-De, Yan, Maolin, Ying, Mingang, Zhang, Ling, Zhang, Xuewen, Zeng, Zhao Chong, Zhang, Yubao, Zhang, Zhiwei, Zhou, Jie, Zhou, Cuncai, Zhou, Jun, Zhou, Ledu, Zhou, Xinmin, Zhu, Ji, Zhu, Zhenyu, Zhang, Qi, Li, Qiu, Cheng, Shuqun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9801175/
https://www.ncbi.nlm.nih.gov/pubmed/36589726
http://dx.doi.org/10.1159/000526038

Ejemplares similares

Ejemplares similares